Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Solid tumors, including breast cancer, exhibit poor response to immune therapies.
• Myeloid cells (MCs), such as macrophages, play a critical role in mediating resistance to cancer treatments.
• Cholesterol metabolism significantly influences macrophage function and cancer progression.

Purpose of the Study:

• To identify regulators of cholesterol homeostasis in MCs that impact cancer outcomes.
• To investigate the role of the cholesterol efflux protein ABCA1 in macrophage-mediated anti-tumor immunity.
• To explore the therapeutic potential of modulating ABCA1 in myeloid cells for cancer treatment.

Main Methods:

• Screening of MC-expressed cholesterol homeostasis regulators.
• Assessment of ABCA1 function in macrophage anti-tumor activities (e.g., tumor infiltration, angiogenesis, T cell support).
• Mechanistic studies involving AKT isoforms and PI3K signaling pathways.
• Analysis of correlations between ABCA1, VEGFA, and CD8+ T cell activity in clinical samples.
• Evaluation of tumor growth, metastasis, and immune therapy response in MC-specific ABCA1 knockout mice.

Main Results:

• ABCA1 was identified as a key regulator of cholesterol homeostasis in MCs.
• ABCA1 enhances macrophage anti-tumor functions, including improved tumor infiltration and CD8+ T cell support, while reducing angiogenesis and efferocytosis.
• Mechanisms involve PI3K-dependent and independent AKT signaling.
• Clinical data show correlations between macrophage ABCA1, reduced angiogenesis (VEGFA), and increased CD8+ T cell activity.
• Loss of MC-specific ABCA1 leads to increased tumor growth, metastasis, and resistance to immune therapy.

Conclusions:

• ABCA1 expression in myeloid cells is crucial for mounting an effective anti-tumor immune response.
• Targeting ABCA1 in MCs represents a novel strategy to overcome resistance to cancer immune therapy.
• Modulating ABCA1 activity in myeloid cells holds significant therapeutic potential for solid tumors.